Novartis AG (VTX:NOVN) received a CHF 90 price objective from investment analysts at HSBC Holdings plc in a research note issued on Thursday. The brokerage currently has a “buy” rating on the stock.

Several other equities research analysts have also issued reports on the stock. Jefferies Group LLC set a CHF 103 price target on shares of Novartis AG and gave the company a “buy” rating in a research note on Friday, June 23rd. Barclays PLC set a CHF 65 price target on shares of Novartis AG and gave the company a “sell” rating in a research note on Friday, June 2nd. Deutsche Bank AG set a CHF 78 price target on shares of Novartis AG and gave the company a “neutral” rating in a research note on Wednesday, June 21st. Morgan Stanley set a CHF 88 price target on shares of Novartis AG and gave the company a “buy” rating in a research note on Wednesday, July 26th. Finally, Berenberg Bank set a CHF 85 price target on shares of Novartis AG and gave the company a “neutral” rating in a research note on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of CHF 85.

Novartis AG (VTX NOVN) traded up 0.06% during trading on Thursday, hitting CHK 81.00. 2,843,258 shares of the stock were exchanged. Novartis AG has a 12-month low of CHK 67.40 and a 12-month high of CHK 84.35. The stock has a 50 day moving average price of CHK 80.90 and a 200-day moving average price of CHK 78.38. The firm has a market capitalization of CHK 189.77 billion and a PE ratio of 29.57.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/09/10/hsbc-holdings-plc-analysts-give-novartis-ag-novn-a-chf-90-price-target.html.

About Novartis AG

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis AG (VTX:NOVN)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.